News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Day In Review: Pozen, Inc. (POZN) Inks Pain Deal With AstraZeneca PLC (AZN)



8/2/2006 7:30:07 PM

August 2, 2006 -- Pozen out-licensed its new pain compound to AstraZeneca in a deal worth up to $375 million; GTC Biotherapeutics won European approval for ATryn; Salix received FDA approval for MoviPrep; Avant received a $21 million grant from the Gates Foundation for a cholera vaccine; Pain Thera and King Pharma began a Phase I test of a new abuse-resistant painkiller; ISTA Pharma in-licensed US rights to an allergic conjunctivitis drug; Gene Logic will reduce staffing in its Genomics Division by 80 positions; and GPC Biotech began a Phase II test of satraplatin. The Centient Biotech 200™ moved up 20.5 points to 3677.66, a gain of .56%. More details...

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES